Omecamtiv mecarbil (OM) is a putative positive inotropic tool for treatment of systolic heart dysfunction, based on the finding that in vivo it increases the ejection fraction and in vitro it prolongs the actin-bond life time of the cardiac and slow-skeletal muscle isoforms of myosin. OM action in situ, however, is still poorly understood as the enhanced Ca-sensitivity of the myofilaments is at odds with the reduction of force and rate of force development observed at saturating Ca. Here we show, by combining fast sarcomere-level mechanics and ATPase measurements in single slow demembranated fibres from rabbit soleus, that the depressant effect of OM on the force per attached motor is reversed, without effect on the ATPase rate, by physiological concentrations of inorganic phosphate (Pi) (1-10 mM). This mechanism could underpin an energetically efficient reduction of systolic tension cost in OM-treated patients, whenever [Pi] increases with heart-beat frequency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341760PMC
http://dx.doi.org/10.1038/s41467-020-17143-2DOI Listing

Publication Analysis

Top Keywords

omecamtiv mecarbil
8
orthophosphate increases
4
increases efficiency
4
efficiency slow
4
slow muscle-myosin
4
muscle-myosin isoform
4
isoform presence
4
presence omecamtiv
4
mecarbil omecamtiv
4
mecarbil putative
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!